$4.40
3.30% today
Nasdaq, Apr 04, 08:43 pm CET
ISIN
US47010C3007
Symbol
JAGX
Sector
Industry

Jaguar Health, Inc. Stock price

$4.55
-9.85 68.40% 1M
-28.20 86.11% 6M
-20.70 81.98% YTD
-106.60 95.91% 1Y
-80,095.45 99.99% 3Y
-170,432.95 100.00% 5Y
-2,402,662,495.45 100.00% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.12 2.57%
ISIN
US47010C3007
Symbol
JAGX
Sector
Industry

Key metrics

Market capitalization $3.07m
Enterprise Value $33.30m
P/E (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales 2.85
P/S ratio (TTM) P/S ratio 0.26
P/B ratio (TTM) P/B ratio 0.33
Revenue growth (TTM) Revenue growth 19.75%
Revenue (TTM) Revenue $11.69m
EBIT (operating result TTM) EBIT $-30.83m
Cash position $8.00m
EPS (TTM) EPS $-233.19
P/E forward negative
P/S forward 0.21
EV/Sales forward 1.66
Short interest 5.44%
Show more

Is Jaguar Health, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Jaguar Health, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Jaguar Health, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Jaguar Health, Inc.:

Buy
100%

Financial data from Jaguar Health, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
12 12
20% 20%
100%
- Direct Costs 4.31 4.31
5% 5%
37%
7.38 7.38
31% 31%
63%
- Selling and Administrative Expenses 19 19
4% 4%
165%
- Research and Development Expense 17 17
11% 11%
141%
-28 -28
10% 10%
-244%
- Depreciation and Amortization 2.36 2.36
1% 1%
20%
EBIT (Operating Income) EBIT -31 -31
9% 9%
-264%
Net Profit -38 -38
7% 7%
-329%

In millions USD.

Don't miss a Thing! We will send you all news about Jaguar Health, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Jaguar Health, Inc. Stock News

Neutral
Accesswire
3 days ago
SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / April 1, 2025 / Jaguar Health, Inc. ( NASDAQ:JAGX ) ("Jaguar" or "the Company"), today announced the closing of its previously announced private placement. Jaguar's president and chief executive officer Lisa Conte, as well as other members of the Company's board of directors and other C-suite and senior executives of Jaguar along with selected insti...
Neutral
Seeking Alpha
4 days ago
Jaguar Health, Inc. (NASDAQ:JAGX ) Q4 2024 Earnings Conference Call March 31, 2025 8:30 AM ET Company Participants Conference Call Participants Operator Greetings, and welcome to the Jaguar Health Investor Webcast. Before I turn the call over to management, I'd like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the c...
Neutral
Accesswire
4 days ago
The total net revenue for the year ended December 31, 2024 of approximately $11.7 million for prescription and non-prescription products, including license revenue, increased approximately 20% versus net revenue of $9.8 million for the year ended December 31, 2023 The total net Q4 2024 revenue of approximately $3.5 million for prescription and non-prescription products, including license revenu...
More Jaguar Health, Inc. News

Company Profile

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. Its products include Canalevia, Equilevia, and Neonorm. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Head office United States
CEO Lisa Conte
Employees 49
Founded 2013
Website www.jaguar.health

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today